Loading the evidence…
Follow an intervention from preclinical studies to human trials and reported outcomes.
| THERAPY / MECHANISM | INJURY MODELS | STUDIES | REPORTED OUTCOME | Open record |
|---|---|---|---|---|
| Platelet-derived growth factor BB in gelatin hydrogel sheets Platelet-derived growth factor receptor agonist (AGONIST) | Other · Wound +1 | 42012–2015 | No trauma translation | |
| Povidone-iodine 0.5% Drug | Wound | 12017 | No trauma translation | |
| Propranolol Beta-1 adrenergic receptor antagonist (ANTAGONIST); Beta-2 adrenergic receptor antagonist (ANTAGONIST) | TBI · Haemorrhage/shock +3 | 111983–2019 | No trauma translation | |
| Pycnogenol, pine bark extract Nutraceutical | Wound | 12017 | Not approved | |
| Recombinant human bone morphogenetic protein-2 (rhBMP-2) Recombinant human BMP-2 protein; ChEMBL get_mechanism returned SIX records, all AGONIST, all direct_interaction and disease_efficacy true (mec_id 9669 BMPR1A CHEMBL5275, 9677 BMPR1B CHEMBL5476, 9672 BMPR2 CHEMBL5467, 9680 ACVR1 CHEMBL5903, 9678 ACVR2A CHEMBL5616, 9671 ACVR2B CHEMBL5466). USAN stem -ermin (-otermin), 2001, defined as bone morphogenetic protein growth factors. ATC M05BC01. EMA cross-references Inductos (human) and Truscient (veterinary). Approved 2002, withdrawn_flag FALSE, black_box_warning FALSE, therapeutic_flag TRUE, dosed_ingredient TRUE. | Spinal cord injury · Wound | 12009–2011 | Approved for trauma | |
| Recombinant human decorin Biologic | Wound · TBI +1 | 42010–2020 | Not approved | |
| Recombinant human insulin-like growth factor-1 (hIGF-1) Insulin-like growth factor I receptor agonist (AGONIST) | TBI · Haemorrhage/shock +1 | 32018–2020 | No trauma translation | |
| Resveratrol Nutraceutical | Chemical/toxin · Radiation +7 | 192003–2020 | Not approved | |
| Rosiglitazone Peroxisome proliferator-activated receptor gamma agonist | Wound · Ischaemia-reperfusion +4 | 92011–2020 | Failed | |
| Sciatic peripheral nerve block with ropivacaine Sodium channel alpha subunit blocker (BLOCKER) | Wound · Other | 32016–2019 | No trauma translation | |
| Sesamin Nutraceutical | Wound | 12020 | Not approved | |
| Sildenafil Phosphodiesterase 5A inhibitor (INHIBITOR) | Radiation · Other +5 | 102011–2020 | No trauma translation | |
| Simvastatin HMG-CoA reductase inhibitor (INHIBITOR), direct interaction, disease efficacy true. | TBI · Chemical/toxin +7 | 152003–2020 | No trauma translation | |
| Substance P Hormone | Ischaemia-reperfusion · Wound +1 | 32013–2019 | Not approved | |
| Tetrodotoxin or saxitoxin, alone or combined with dexmedetomidine or clonidine Drug | Wound | 12015 | Not approved | |
| Topical 2% mupirocin ointment for scald wound infection and intraperitoneal daptomycin for sepsis Mupirocin, a topical antibacterial that inhibits bacterial isoleucyl-tRNA synthetase (combination also includes intraperitoneal daptomycin). | Burn · Wound | 22014–2018 | No trauma translation | |
| Topical ointment containing nitric oxide-loaded zinc-exchanged zeolite A, releasing nitric oxide on contact with water Soluble guanylate cyclase activator | Wound | 12013 | No trauma translation | |
| Unfractionated heparin Antithrombin-III activator; inhibits coagulation by activating antithrombin III, which then binds factor X | TBI · Wound | 32012–2017 | No trauma translation | |
| Vancomycin, applied as a mesh presoak Peptidoglycan inhibitor | Wound | 12012 | No trauma translation | |
| Zinc Nutraceutical | Wound · Radiation | 31980–2017 | No trauma translation | |
| Zymosan and glucan (macrophage stimulators); levamisole (immunomodulator) Nicotinic acetylcholine receptor alpha subunit agonist (ChEMBL mechanism on salt CHEMBL1770). Only the levamisole component resolved; zymosan and glucan are crude yeast cell-wall preparations with no ChEMBL entry. | Wound | 11983 | Failed |
Study counts are reported at therapy level and can differ from the number of itemised publications. Outcomes are research classifications, not treatment recommendations.